Summary & Overview
HCPCS A2014: Omeza Collagen Matrix, per 100 mg
HCPCS Level II code A2014 denotes the Omeza collagen matrix or Omeza complete matrix, billed per 100 mg. The code captures use of a biologic collagen matrix product commonly employed as a soft-tissue graft or scaffold in wound care, reconstructive surgery, and related outpatient procedures. Nationally, products billed under A2014 matter for device and implant spend, supply chain management, and coverage policies for biologic scaffolds.
Key payers considered in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise synthesis of clinical context for use of the product, payer coverage considerations, and the typical places of service where the product is supplied. The publication summarizes common billing modifiers associated with supply/implant lines, notes the absence of taxonomies and ICD-10 pairings in the provided input, and identifies where Data not available in the input prevents deeper linkage to diagnoses or related codes.
This summary provides benchmarks and policy-relevant points to inform billing teams, revenue cycle managers, and clinical procurement leaders about the coding designation for Omeza collagen matrix products. The content highlights what to expect in claims submission and where to seek payer-specific policy language for coverage and prior authorization requirements.
Billing Code Overview
HCPCS Level II code A2014 describes Omeza collagen matrix or Omeza complete matrix, per 100 mg. This code represents a biologic collagen matrix product used as a soft-tissue graft or scaffold in wound management and reconstructive procedures.
Service type: Biologic implant / soft-tissue graft product
Typical site of service: Outpatient surgical settings, ambulatory surgery centers, and hospital outpatient departments
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient presents with a chronic full-thickness periodontal defect and inadequate soft-tissue and bony scaffolding following tooth extraction and previous failed grafting. The oral and maxillofacial surgeon or periodontist evaluates the site and elects to place a collagen matrix graft (Omeza collagen matrix or Omeza complete matrix) to provide biologic scaffold for soft-tissue regeneration and wound stabilization. The usual clinical workflow includes preoperative assessment and consent, local anesthesia (or sedation if required), surgical site debridement and preparation, trimming and placement of the collagen matrix sized to the defect (billed per 100 mg with A2014), fixation or suturing of the matrix into position, and standard postoperative instructions with follow-up visits to assess integration and healing. Typical settings are ambulatory surgical centers, outpatient hospital clinics, dental offices with surgical capability, or office-based oral surgery suites. Common clinical indications include periodontal regeneration, ridge preservation after extraction, soft-tissue augmentation adjacent to implants, and coverage of small intraoral defects when a biologic scaffold is indicated.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier — default. | Use when no special circumstances or modifiers apply. |